#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myocarditis Plasma cell myeloma recurrent Philadelphia positive acute lymphocytic leukaemia Hereditary spastic paraplegia Neurotrophic keratopathy Short stature Mixed-type liposarcoma Acromegaly High-grade B-cell lymphoma Fibrodysplasia ossificans progressiva Primitive neuroectodermal tumour Haemophilia A without inhibitors Leiomyosarcoma Fibrosarcoma metastatic PIK3CA related overgrowth spectrum More trials…

    Learn about Rare Diseases

    Immunodeficiency congenital Sjogren’s syndrome – Treatment Urea cycle disorder Hypereosinophilic syndrome – Basic Information Lysosomal storage disorder – Treatment Mucopolysaccharidosis I – Trials in Disease Mastocytosis – Basic Information Krabbe’s disease – Treatment Paraneoplastic neurological syndrome – Trials in Disease Mantle cell lymphoma stage III More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mps-215 PRILOCAINE HYDROCHLORIDE Vx-522 TRIACYLGLYCEROL LIPASE Fluorouracil Sodium Daunorubicin Chlorhexidine Dihydrochloride Donepezil Siremadlin REGN7544 Rigosertib Sodium Epoetin Alfa Lovastatin Itacitinib Xylitol Sparsentan Mirabegron NAVENIBART Catequentinib Dihydrochloride Lurasidone More therapies…

    Learn about Your Condition

    Mesothelioma malignant Peptostreptococcus infection Medulloblastoma recurrent Toxic epidermal necrolysis Muscle injury Nephrolithiasis Proteus syndrome Diabetic retinal oedema Endocrine disorder Medication overuse headache Colorectal cancer stage III Metastases to lymph nodes Arterial disorder Plasma cell leukaemia Biliary cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. ICMR (International Center for Medical Research)

ICMR (International Center for Medical Research)

Calle De Cinca 21, Madrid, 28002, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    • Eczema
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Czechia France Germany Poland Spain

  • A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata

    Recruiting

    2 1
    Investigated Diseases:
    • Alopecia areata
    Bulgaria Germany Poland Romania Spain

  • Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Ustekinumab
    • Deucravacitinib
    Belgium Bulgaria Czechia Denmark France Germany +6

  • A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Bimekizumab
    Czechia Denmark France Germany Hungary Italy +2

  • Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

    Recruiting

    2 1
    Investigated Drugs:
    • Apg777
    Czechia France Germany Hungary Poland Spain

  • A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

    Recruiting

    3 1 1
    Investigated Drugs:
    • Lebrikizumab
    Bulgaria France Germany Italy Poland Spain

  • Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Remibrutinib
    Belgium Bulgaria Czechia France Germany Greece +6

  • Study of early versus late risankizumab treatment to evaluate immune cell response in patients with moderate to severe psoriasis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Risankizumab
    Spain

  • Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    • Deucravacitinib
    France Germany Hungary Italy Poland Spain

  • ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    2 1
    Investigated Diseases:
    • Psoriasis
    Germany Spain
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!